JDJeroen Den Dunnen

Jeroen Den Dunnen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeroen Den Dunnen has a total of 333 co-authors. Here are the top co-authors by number of shared publications:

  • Hung-Jen Chen

    Center for Infection and Molecular Medicine, Amsterdam institute for Immunology and Infectious diseases, Amsterdam University Medical Center (UMC) University of Amsterdam Amsterdam The Netherlands

    11 shared publications
  • Gestur Vidarsson

    Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands

    10 shared publications
  • Willianne Hoepel

    Center for Experimental and Molecular Medicine, Amsterdam University Medical Centers (UMC), University of Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, Netherlands

    10 shared publications
  • Willianne Hoepel

    Center for Experimental and Molecular Medicine, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers

    9 shared publications
  • Dominique L. P. Baeten

    Amsterdam Rheumatology and Immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, University of Amsterdam , 1105 AZ Amsterdam

    8 shared publications
  • Ivo S. Hansen

    Amsterdam Rheumatology and Immunology Center, Location Academic Medical Center, Amsterdam, The Netherlands

    7 shared publications

Latest Publications

  • Open Access

    Hyperinflammation by Human Macrophages Induced by SARS‐CoV‐2 Anti‐Spike IgG Is Dependent on Glucose and Fatty Acid Metabolism

    by Chiara E. Geyer, Luís Almeida, Lynn Mes, Frank Otto, W. Ashwin Mak, Graham A. Heieis, Jennifer Veth, Steven W. de Taeye, Tom G. Caniels, Tom P. L. Bijl, et al.

    Severe COVID‐19 is an immunological disorder characterized by excessive immune activation following infection with SARS‐CoV‐2, which typically occurs around the time of seroconversion. Anti‐spike IgG of critically ill COVID‐19 patients induces excessive inflammation by activation of Fc gamma receptors (FcγRs) on human alveolar macrophages, leading to tissue damage, pulmonary edema, and coagulopathy. While metabolic reprogramming of immune cells is critical for the induction of inflammatory responses, still little is known about the metabolic pathways that are involved in COVID‐19‐specific hyperinflammation. In this study, we identified that anti‐spike IgG immune complexes (ICs) induce rapid metabolic reprogramming of alveolar macrophages, which is essential for the induction of inflammation. Through functional inhibition, we identified that glycolysis, fatty acid synthesis, and pentose phosphate pathway (PPP) activation are critical for anti‐spike IgG‐induced hyperinflammation. Remarkably, while excessive proinflammatory cytokine production by macrophages is critically dependent on simultaneous stimulation with viral stimuli and anti‐spike IgG complexes, we show that the required metabolic reprogramming is specifically driven by anti‐spike IgG complexes. These findings provide new insights into the metabolic pathways driving hyperinflammation by macrophages in the context of severe COVID‐19. Targeting of these pathways may reveal new possibilities to counteract pathological inflammatory responses in severe COVID‐19 and related diseases.

  • Open Access

    Anti‐SARS‐CoV‐2 Spike IgA2 Induces Inflammation by Human Macrophages

    by Lynn Mes, Jennifer Veth, Julie Van Coillie, Jim B. D. Keijser, Elise Mantel, Richard van der Mast, Theo Rispens, Gestur Vidarsson, Marjolein van Egmond, Jeroen Den Dunnen, et al.

    Severe COVID‐19 is an immunological disorder characterized by a hyper‐inflammatory reaction of the immune system. SARS‐CoV‐2 anti‐spike antibodies of the IgG isotype are known to strongly contribute to this hyperinflammation by overactivation of alveolar macrophages. However, while the pathogenic function of IgG has been extensively studied, very little is known about the function of IgA, the most abundant immunoglobulin isotype in the airways. Although IgA is generally considered noninflammatory, in this study, we show that anti‐spike IgA induces pronounced proinflammatory responses. We demonstrate that stimulation of macrophages with anti‐spike IgA immune complexes in combination with a viral stimulus amplifies proinflammatory cytokine production. This IgA‐induced inflammation is particularly driven by IgA2, the IgA subclass that is increased in the plasma of severely ill COVID‐19 patients. We identified that IgA2‐induced inflammation is predominantly dependent on FcαRI‐Syk signaling. Mechanistically, IgA2‐induced inflammation is linked to enhanced glycolysis and altered mitochondrial function, indicating subclass‐specific immunometabolic reprogramming. Taken together, these data indicate a pathogenic role for IgA2 in severe COVID‐19 and highlight its signaling cascades and metabolic pathways as potential druggable targets to counteract hyperinflammation in severe coronavirus infections, such as COVID‐19, SARS, MERS, and potential future outbreaks.


  • Open Access

    Testosterone and estradiol reduce inflammation of human macrophages induced by anti‐SARS‐CoV‐2 IgG

    by Sona Allahverdiyeva, Chiara E. Geyer, Jennifer Veth, Laura M. de Vries, Steven W. de Taeye, Marit J. van Gils, Jeroen Den Dunnen, Hung‐Jen Chen

    COVID‐19, the disease caused by SARS‐CoV‐2, particularly causes severe inflammatory disease in elderly, obese, and male patients. Since both aging and obesity are associated with decreased testosterone and estradiol expression, we hypothesized that decreased hormone levels contribute to excessive inflammation in the context of COVID‐19. Previously, we and others have shown that hyperinflammation in severe COVID‐19 patients is induced by the production of pathogenic anti‐spike IgG antibodies that activate alveolar macrophages. Therefore, we developed an in vitro assay in which we stimulated human macrophages with viral stimuli, anti‐spike IgG immune complexes, and different sex hormones. Treatment with levels of testosterone reflecting young adults led to a significant reduction in TNF and IFN‐γ production by human macrophages. In addition, estradiol significantly attenuated the production of a very broad panel of cytokines, including TNF, IL‐1β, IL‐6, IL‐10, and IFN‐γ. Both testosterone and estradiol reduced the expression of Fc gamma receptors IIa and III, the two main receptors responsible for anti‐spike IgG‐induced inflammation. Combined, these findings indicate that sex hormones reduce the inflammatory response of human alveolar macrophages to specific COVID‐19‐associated stimuli, thereby providing a potential immunological mechanism for the development of severe COVID‐19 in both older male and female patients.


  • Open Access

    Transfer of IgG from Long COVID patients induces symptomology in mice

    by Hung-Jen Chen, Brent Appelman, Hanneke Willemen, Amelie Bos, Judith Prado, Chiara. E. Geyer, Patrícia Silva Santos Ribeiro, Sabine Versteeg, Mads Delbo Larsen, Eline Schüchner, et al.

    SARS-CoV-2 infections worldwide led to a surge in cases of Long COVID, a post-infectious syndrome. It has been hypothesized that autoantibodies play a crucial role in the development of Long COVID and other syndromes, such as fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). In this study, we tested this hypothesis by passively transferring total IgG from Long COVID patients to mice. Using Glial Fibrillary Acidic Protein (GFAP) and type-I interferon expression, we stratified patients into three Long COVID subgroups, each with unique plasma proteome signatures. Remarkably, IgG transfer from the two subgroups, which are characterized by higher plasma levels of neuronal proteins and leukocyte activation markers, induced pronounced and persistent sensory hypersensitivity with distinct kinetics. Conversely, IgG transfer from the third subgroup, which are characterized by enriched skeletal and cardiac muscle proteome profiles, reduced locomotor activity in mice without affecting their motor coordination. These findings demonstrate that transfer of IgG from Long COVID patients to mice replicates disease symptoms, underscoring IgG’s causative role in Long COVID pathogenesis. This work proposes a murine model that mirrors Long COVID’s pathophysiological mechanisms, which may be used as a tool for screening and developing targeted therapeutics.


  • Open Access

    Platelets of COVID-19 patients display mitochondrial dysfunction, oxidative stress, and energy metabolism failure compatible with cell death

    by Valentine Léopold, Osoul Chouchane, Joe M. Butler, Alex R. Schuurman, Erik H.A. Michels, Justin de Brabander, Bauke V. Schomakers, Michel van Weeghel, Daisy I. Picavet-Havik, Anita E. Grootemaat, et al.


  • Open Access

    Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19

    by Chiara E Geyer, Hung-Jen Chen, Alexander P Bye, Xue D Manz, Denise Guerra, Tom G Caniels, Tom Pl Bijl, Guillermo R Griffith, Willianne Hoepel, Steven W de Taeye, et al.

    Previously, we and others have shown that SARS-CoV-2 spike-specific IgG antibodies play a major role in disease severity in COVID-19 by triggering macrophage hyperactivation, disrupting endothelial barrier integrity, and inducing thrombus formation. This hyperinflammation is dependent on high levels of anti-spike IgG with aberrant Fc tail glycosylation, leading to Fcγ receptor hyperactivation. For development of immune-regulatory therapeutics, drug specificity is crucial to counteract excessive inflammation whereas simultaneously minimizing the inhibition of antiviral immunity. We here developed an in vitro activation assay to screen for small molecule drugs that specifically counteract antibody-induced pathology. We identified that anti-spike-induced inflammation is specifically blocked by small molecule inhibitors against SYK and PI3K. We identified SYK inhibitor entospletinib as the most promising candidate drug, which also counteracted anti-spike-induced endothelial dysfunction and thrombus formation. Moreover, entospletinib blocked inflammation by different SARS-CoV-2 variants of concern. Combined, these data identify entospletinib as a promising treatment for severe COVID-19.


  • Open Access

    IgA2 immune complexes selectively promote inflammation by human CD103+ dendritic cells

    by Lynn Mes, Ulrike Steffen, Hung-Jen Chen, Jennifer Veth, Willianne Hoepel, Guillermo Romeo Griffith, Georg Schett, Jeroen Den Dunnen

    While immunoglobulin A (IgA) is well known for its neutralizing and anti-inflammatory function, it is becoming increasingly clear that IgA can also induce human inflammatory responses by various different immune cells. Yet, little is known about the relative role of induction of inflammation by the two IgA subclasses i.e. IgA1, most prominent subclass in circulation, and IgA2, most prominent subclass in the lower intestine. Here, we set out to study the inflammatory function of IgA subclasses on different human myeloid immune cell subsets, including monocytes, and in vitro differentiated macrophages and intestinal CD103+ dendritic cells (DCs). While individual stimulation with IgA immune complexes only induced limited inflammatory responses by human immune cells, both IgA subclasses strongly amplified pro-inflammatory cytokine production upon co-stimulation with Toll-like receptor (TLR) ligands such as Pam3CSK4, PGN, and LPS. Strikingly, while IgA1 induced slightly higher or similar levels of pro-inflammatory cytokines by monocytes and macrophages, respectively, IgA2 induced substantially more inflammation than IgA1 by CD103+ DCs. In addition to pro-inflammatory cytokine proteins, IgA2 also induced higher mRNA expression levels, indicating that amplification of pro-inflammatory cytokine production is at least partially regulated at the level of gene transcription. Interestingly, cytokine amplification by IgA1 was almost completely dependent on Fc alpha receptor I (FcαRI), whilst blocking this receptor only partially reduced cytokine induction by IgA2. In addition, IgA2-induced amplification of pro-inflammatory cytokines was less dependent on signaling through the kinases Syk, PI3K, and TBK1/IKKϵ. Combined, these findings indicate that IgA2 immune complexes, which are most abundantly expressed in the lower intestine, particularly promote inflammation by human CD103+ intestinal DCs. This may serve an important physiological function upon infection, by enabling inflammatory responses by this otherwise tolerogenic DC subset. Since various inflammatory disorders are characterized by disturbances in IgA subclass balance, this may also play a role in the induction or exacerbation of chronic intestinal inflammation.


  • Open Access

    Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19

    by Chiara E. Geyer, Hung-Jen Chen, Alexander P. Bye, Xue D. Manz, Denise Guerra, Tom G. Caniels, Tom P.L. Bijl, Guillermo R. Griffith, Willianne Hoepel, Steven W. de Taeye, et al.

    Summary: Previously, we and others have shown that SARS-CoV-2 spike-specific IgG antibodies play a major role in disease severity in COVID-19 by triggering macrophage hyperactivation, disrupting endothelial barrier integrity, and inducing thrombus formation. This hyper-inflammation is dependent on high levels of anti-spike IgG with aberrant Fc tail glycosylation, leading to Fcγ receptor hyper-activation. For development of immune-regulatory therapeutics, drug specificity is crucial to counteract excessive inflammation while simultaneously minimizing inhibition of antiviral immunity. We here developed an in vitro activation assay to screen for small molecule drugs that specifically counteract antibody-induced pathology. We identified that anti-spike induced inflammation is specifically blocked by small molecule inhibitors against SYK and PI3K. We identified SYK inhibitor entospletinib as the most promising candidate drug, which also counteracted anti-spike-induced endothelial dysfunction and thrombus formation. Moreover, entospletinib blocked inflammation by different SARS-CoV-2 variants of concern. Combined, these data identify entospletinib as a promising treatment for severe COVID-19. Graphical

  • Open Access

    The BNT162b2 mRNA SARS-CoV-2 Vaccine Induces Transient Afucosylated IgG1 in Naive But Not in Antigen-Experienced Vaccinees

    by Julie Van Coillie, Tamas Pongracz, Johann Rahmöller, Hung-Jen Chen, Chiara E. Geyer, Lonneke A. van Vught, Jana S. Buhre, Tonći Šuštić, Thijs L. J. van Osch, Maurice Steenhuis, et al.

    Background: Afucosylated IgG responses have been found only against membrane-embedded epitopes, including anti-S in SARS-CoV-2 infections. These responses, intrinsically protective through enhanced FcgRIIIa binding, also trigger exacerbated pro-inflammatory responses in severe COVID-19. We investigated if the BNT162b2 SARS-CoV-2 mRNA also induced afucosylated IgG responses. Methods: Blood from vaccinees during the first vaccination wave was collected. MS was used to study anti-S IgG1-Fc glycoprofiling. Responsiveness of alveolar-like macrophages to produce proinflammatory cytokines in presence of sera and antigen was tested. Antigen-specific B cells were characterized and glycosyltransferase levels were investigated by FACS. Findings: Transient afucosylated anti-S IgG1 responses were found in naive vaccinees, but not in antigen-experienced vaccinees. All vaccinees had increased galactosylation and sialylation of anti-S IgG1. Both naive and antigen-experienced vaccinees showed relative low macrophage activation potential as expected due to the low antibody levels for naive individuals with afucosylated IgG, and high fucosylation levels for antigen-experienced individuals with high levels of anti-S. Afucosylation levels correlated with FUT8 expression in antigen-specific plasma cells in naive individuals. Importantly, low fucosylation of anti-S IgG upon seroconversion correlated with high IgG levels after the second dose. Interpretation: Here, for the first time, we show that BNT162b2 mRNA vaccination induces transient afucosylated anti-S IgG1 responses in naive individuals. This observation warrants further studies to elucidate the clinical context in which potent afucosylated responses would be preferred. Funding: LSBR 1721, 1908; ZonMW 10430012010021, 09150161910033; DFG 398859914, 400912066, 390884018; PMI; DOI4-Nr. 3; H2020-MSCA-ITN 721815. Declaration of Interest: The authors declare that they have no conflicts of interest. Ethical Approval: The ethics committee of the AUMC approved the study.


  • Open Access

    The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not antigen-experienced vaccinees

    by Julie Van Coillie, Tamas Pongracz, Johann Rahmöller, Hung-Jen Chen, Chiara Geyer, Lonneke A. van Vlught, Jana S. Buhre, Tonći Šuštić, Thijs L. J. van Osch, Maurice Steenhuis, et al.

    The onset of severe SARS-CoV-2 infection is characterized by the presence of afucosylated IgG1 responses against the viral spike (S) protein, which can trigger exacerbated inflammatory responses. Here, we studied IgG glycosylation after BNT162b2 SARS-CoV-2 mRNA vaccination to explore whether vaccine-induced S protein expression on host cells also generates afucosylated IgG1 responses. SARS-CoV-2 naive individuals initially showed a transient afucosylated anti-S IgG1 response after the first dose, albeit to a lower extent than severely ill COVID-19 patients. In contrast, previously infected, antigen-experienced individuals had low afucosylation levels, which slightly increased after immunization. Afucosylation levels after the first dose correlated with low fucosyltransferase 8 (FUT8) expression levels in a defined plasma cell subset. Remarkably, IgG afucosylation levels after primary vaccination correlated significantly with IgG levels after the second dose. Further studies are needed to assess efficacy, inflammatory potential, and protective capacity of afucosylated IgG responses. One sentence summary A transient afucosylated IgG response to the BNT162b2 mRNA vaccine was observed in naive but not in antigen-experienced individuals, which predicted antibody titers upon the second dose.